Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewHighly potent NMDA antagonist; more active isomer. Shows some selectivity for GluN2A (formally NR2A) containing receptors (Ki values are 0.041, 0.27, 0.63 and 1.99 μM for inhibition of GluN2A-, GluN2B-, GluN2C- and GluN2D-containing recombinant NMDA receptors respectively).
Racemate also available.
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
M. Wt | 252.21 |
Formula | C8H17N2O5P |
Storage | Desiccate at RT |
CAS Number | 126453-07-4 |
PubChem ID | 6603754 |
InChI Key | CUVGUPIVTLGRGI-SSDOTTSWSA-N |
Smiles | [H][C@@]1([C@](O)=O)NCCN(CCCP(O)(O)=O)C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
water | 25.22 | 100 |
The following data is based on the product molecular weight 252.21. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 3.96 mL | 19.82 mL | 39.65 mL |
5 mM | 0.79 mL | 3.96 mL | 7.93 mL |
10 mM | 0.4 mL | 1.98 mL | 3.96 mL |
50 mM | 0.08 mL | 0.4 mL | 0.79 mL |
References are publications that support the biological activity of the product.
Feng et al (2004) Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid. Br.J.Pharmacol. 141 508 PMID: 14718249
Aebischer et al (1989) Synthesis and NMDA antagonistic properties of the enantiomers of 4-(3-phosphonopropyl)piperazine-2-carboxylic acid (CPP) and of the unsaturated analogue (E)-4-(3-phosphono-2-enyl)piperazine-2-carboxylic acid (CPP-ene). Helv.Chim.Acta 72 1043
If you know of a relevant reference for (R)-CPP, please let us know.
Keywords: (R)-CPP, (R)-CPP supplier, Potent, NMDA, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, 0247, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for (R)-CPP include:
Vigot et al (2006) Differential compartmentalization and distinct functions of GABAB receptor variants. Neuron 50 589 PMID: 16701209
Maeder et al (2018) The THO Complex Coordinates Transcripts for Synapse Development and DA Neuron Survival. Cell 174 1436 PMID: 30146163
Sancho and Bloodgood (2018) Functional Distinctions between Spine and Dendritic Synapses Made onto Parvalbumin-Positive Interneurons in Mouse Cortex. Cell Rep 24 2075 PMID: 30134169
Collins et al (2018) Reciprocal Circuits Linking the Prefrontal Cortex with Dorsal and Ventral Thalamic Nuclei. Neuron 98 366 PMID: 29628187
Pan et al (2016) Neuronal firing patterns outweigh circuitry oscillations in parkinsonian motor control. J Clin Invest 126 4516 PMID: 27797341
Tsutsui-Kimura et al (2015) Milnacipran remediates impulsive deficits in rats with lesions of the ventromedial prefrontal cortex. J Neurosci 18 PMID: 25522418
Stephany et al (2014) Plasticity of binocularity and visual acuity are differentially limited by nogo receptor. PLoS One 34 11631 PMID: 25164659
Chaffiol et al (2017) A New Promoter Allows Optogenetic Vision Restoration with Enhanced Sensitivity in Macaque Retina. Mol Ther 25 2546 PMID: 28807567
Mao et al Characterization and subcellular targeting of GCaMP-type genetically-encoded calcium indicators. Nat Commun 3 e1796 PMID: 18350138
Higley et al (2011) Cholinergic interneurons mediate fast VGluT3-dependent glutamatergic transmission in the striatum. PLoS One 6 e19155 PMID: 21544206
Wood et al (2009) Synaptic circuit abnormalities of motor-frontal layer 2/3 pyramidal neurons in an RNA interference model of methyl-CpG-binding protein 2 deficiency. Int J Neuropsychopharmacol 29 12440 PMID: 19812320
Zhang et al (2018) Heparan Sulfate Organizes Neuronal Synapses through Neurexin Partnerships. Cell 174 1450 PMID: 30100184
Fan et al (2018) All-optical synaptic electrophysiology probes mechanism of ketamine-induced disinhibition. Nat Methods 15 823 PMID: 30275587
Chang and Higley (2018) Potassium channels contribute to activity-dependent regulation of dendritic inhibition. Physiol Rep 6 e13747 PMID: 29939492
Do you know of a great paper that uses (R)-CPP from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review (R)-CPP and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.